Our data demonstrate that both the FLLL32 lead compound and its structurally modified analog, FLLL62 are specific inhibitors of the Jak2-STAT3 pathway, which induce apoptosis and down-regulate soluble VEGF production in human RCC cell lines. Here, STAT3 is linked to renal cell carcinoma.